News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Forum: Aktien User: Lirumlarum1

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer Open-label Phase 1b/2 study will evaluate the safety and preliminary efficacy of Anktiva (N-803) and PD-L1 t-haNK in combination with antibody-drug conjugate Trodelvy and low-dose chemotherapy in subjects with advanced triple-negative breast cancer (TNBC) after prior therapy The FDA approved Trodelvy for TNBC in April 2020 based on an overall response rate of 33.3%, with a median duration of response of 7.7 months; 55.6% maintained their response for 6 or more months and 16.7% maintained their response for 12 or more months. Study design is based on results of Phase 1 trial of haNK cells combined with Anktiva and low dose chemo in refractory triple negative breast cancer, where disease control rate of 78% and overall response rate of 67% was reached Enrollment expected to begin in Q3 2021 https://ir.immunitybio.com/news-releases/news-release-details/fda-authorizes-immunitybio-study-anktiva-and-pd-l1-t-hank?field_nir_news_date_value[min]=

ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients Sponsored by the NIAID and AIDS Clinical Trials Group, an “HIV cure study” will evaluate whether IL-15 superagonist AnktivaÔ (N-803) alone or together with broadly neutralizing antibodies can control HIV following interruption of antiretroviral therapy (ART). The Phase 1 open-label, randomized study will enroll 46 people living with HIV whose virus has been suppressed by ART for approximately two years, including at least 30 percent cisgender women or transgender men. A second clinical trial studying Anktiva in HIV is being conducted by the U.S. Military HIV Research Program in Thailand. The Phase 2 study is evaluating Anktiva in combination with antiretroviral therapy (ART) during acute HIV infection as an experimental therapy to target and inhibit early establishment of HIV reservoirs in infected individuals. https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-hiv-clinical-pipeline-opening-phase-1-hiv?field_nir_news_date_value[min]=

Artikel der New York Times: (Erwähnt ImmunityBio) We’ll Probably Need Booster Shots for Covid-19. But When? And Which Ones? https://www.google.com/amp/s/www.nytimes.com/2021/06/06/science/covid-vaccine-boosters.amp.html

Dr. Pat Soon-Shiong @DrPatSoonShiong 3. Juni SARS CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralization. T cell vaccine critical in this war against Covid.

ImmunityBio, Inc. @ImmunityBio vor 13 Std. 40 years ago this month the first HIV/AIDS cases were diagnosed in the U.S., while we still don’t have a cure, the global research community has made tremendous progress in developing effective therapeutics. Learn more about our HIV trials here. https://bit.ly/3z8dJue #IBRX

Beim Nicht-muskelinvasiven Harnblasenkarzinom, erreicht ImmunityBio eine komplette Remmissionsrate (CR) von 70%. Keytruda von Merck erreicht 41% CR, Kosten pro 4ml betragen ca. 3037€/5264$ (die Preise sind von Land zu Land unterschiedlich und dies sind nur Preise, welche ich auf verschiedenen Webseiten gefunden habe und nicht einfach dem tagesaktuellen Wechselkurs entsprechen) und bringt einen Jahresumsatz von 14,4 Milliarden Dollar.

-1800+ patients studied -600 worldwide patents - plus. -25 Phase 2/3 trials -40 1/2/3 trials -NMIBC - 70% CR on avg. duration -Keytruda 41% - 14.4B in 2020 -3rd line Pancreatic - MOS 13 months -Pancreatic cancer vaccine in progress -Triple negative Breast Cancer - ORR 67% -M cenk - liquid and solid tumor therapy program -Liquid Tumors: Indolent Non-Hodgkin Lymphoma (iNHL) 78% CR with Rituxin -Ph 1 M-ceNK (N=20): 3,000% Cell Expansion with Potent Killing Across Multiple Cell Lines -Confirmation by NCI Researchers: M-ceNK Potent Activity Across Multiple Cell Types -Multiple Routes of Administration of Same Vaccine Construct to Achieve T-Cell-Mediated & Mucosal Immunity -Sisonke Universal Boost Trial in South Africa (Phase 1/2) Prime (Ad26) + Boost (hAd5 S-Fusion + N-ETSD) N-803 in HIV Phase 1/2

ImmunityBio, Inc. @ImmunityBio 21 hours ago: This USA TODAY article provides an overview of second-generation COVID-19 vaccines; ImmunityBio is one of a few vaccine developers studying multiple delivery routes. https://news.yahoo.com/vaccines-2-0-next-generation-093007959.html

After the acquisition in 2015 by ImmunityBio Inc., VivaBioCell grew and developed rapidly, reaching the market in 2018 with an innovative bioreactor system, the NANT 001. The challenge to improve and increase the cell therapy manufacturing scale led to the development of the NANT XL System, launched in the marketed in 2019. In 2021 VivaBioCell released eventually NANT Maestro, a novel software designed to manage and monitor the entire device pool from a single and centralized dashboard. http://www.vivabiocell.it/

"Das derzeit am weitesten fortgeschrittene Projekt dieser Art ist laut „t-online“ das, des US-Unternehmens ImmunityBio. Vergangenen Monat hat das Unternehmen erste Ergebnisse veröffentlicht, die Grund zur Hoffnung bieten."

Mehrere Jahre wirksam, Schutz vor allen möglichen Corona-Mutanten: Forschende arbeiten an „Super-Vakzin“ https://www.businessinsider.de/wissenschaft/mehrere-jahre-wirksam-forschende-arbeiten-an-super-vakzin-b/

ImmunityBio, Inc. @ImmunityBio 8 hours ago: Recent study shows variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 mRNA vaccinations, but S-specific CD4+T-cell activation is not affected by the mutations in the variants first detected in UK & South Africa.

ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa Studies will provide data on T-cell-based COVID-19 vaccine candidate as a universal boost with four potential routes of administration (subcutaneous shot, sublingual droplet, oral capsule, and intranasal spray) The goal of the vaccine is to activate the entire immune system and potentially provide longer-lasting immune response and head off future variants South African Health Products Regulatory Authority (SAHPRA) has approved an expanded study to test intranasal administration of ImmunityBio’s T-cell-based COVID-19 vaccine candidate hAd5 S+N in subjects previously infected with SARS-CoV-2 Phase 1/2/3 Universal Boost trial is designed to evaluate hAd5 S+N as a boost for South African healthcare workers previously vaccinated with a currently available spike-only antibody-based vaccine In preclinical studies, hAd5 administered subcutaneously plus intranasally (SC + IN) as a dual prime without a boost was as effective in generating humoral and T-cell responses as the SC + IN prime with a boost. https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-expands-trials-t-cell-based-covid-19-vaccine?field_nir_news_date_value[min]=